Hybrid IgA/IgG Polymeric Antibodies
The IgA/IgG hybrid has the pH stability of an IgA molecule The IgA/IgG hybrid has complement fixing activity greater than monomeric IgG molecules. Can produce the IgA/IgG hybrib monoclonal antibodies in large quantities using standard antibody production techniques.
Recombinant antibody therapies
UCLA researchers have engineered IgA/IgG hybrid antibodies that combine characteristics of both IgA and IgG into a single immunoglobulin molecule. The IgG constant region was enhanced with the addition of IgA constant regions. This addition resulted in a molecule that has the pH stability of IgA and greater complement fixing activity than IgG due to its polymeric structure. By utilizing this technology, any variable region can be paired with the IgA/IgG hybrid to yield an immunoglobulin molecule with unique effector functions.
Patent Number: US6284536B1
Application Number: US1999295283A
Inventor: Morrison, Sherie L. | Chintalacharuvu, Koteswara R. | Yoo, Esther Mikyung | Trinh, Kham M. | Coloma, M. Josefina
Priority Date: 20 Apr 1998
Priority Number: US6284536B1
Application Date: 20 Apr 1999
Publication Date: 4 Sep 2001
IPC Current: C07K001600 | C07K001646 | C12P002108 | A61K003800
US Class: 435328 | 4241331 | 4241601 | 4241611 | 435005 | 4350071 | 4350697 | 4350701 | 4353201 | 4353391 | 5303873 | 5360235 | 53602343
Assignee Applicant: The Regents of the University of California
Title: Modified immunoglobulin molecules and methods for use thereof | Modified immunoglobin molecules and methods for use thereof
Usefulness: Modified immunoglobulin molecules and methods for use thereof | Modified immunoglobin molecules and methods for use thereof
Summary: (I) may be used to treat or prevent a systemic, local or mucosal infection in a mammal, bird, reptile or fish. The types of infection that may be treated include bacterial, mycoplasmal, mycobacterial, yeast or parasitic infections, especially HIV, hepatitis, respiratory syncytial virus, influenza or cold viral infections (all claimed).
Novelty: New modified immunoglobulin molecules, useful for treatment and prevention of infectious diseases
Disease Diagnostic/Treatment
HIV
6284536
Background IgA is a polymeric effector molecule of the immune system that mainly acts at mucosal surfaces and is highly resistant to extreme pH conditions, whereas IgG is monomeric and acts in the blood at a narrower pH range. IgG is known for its potent complement activation and, in contrast, IgA is unable to fix complement. Combining the characteristics of IgA and IgG into a single immunoglobulin molecule may produce more effective therapeutic agents. Additional Technologies by these Inventors Tech ID/UC Case 20084/1998-610-0 Related Cases 1998-610-0
USA
